{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:19:44Z","timestamp":1789690784056,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jbc.2025.108240","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T16:05:58Z","timestamp":1737993958000},"page":"108240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A novel FOXM1\u2013BCL2A1 axis determines unfavorable response to venetoclax in AML"],"prefix":"10.1016","volume":"301","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3549-5413","authenticated-orcid":false,"given":"Sanjeev","family":"Raghuwanshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Magdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nissim","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Gartel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2025.108240_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jbc.2025.108240_bib2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2025.108240_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbc.2025.108240_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4161\/cbt.4.2.1508","article-title":"Overview of cell death signaling pathways","volume":"4","author":"Jin","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jbc.2025.108240_bib5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.jbc.2025.108240_bib6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","article-title":"FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal. Transduct Target. Ther."},{"key":"10.1016\/j.jbc.2025.108240_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/A:1008255511404","article-title":"High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia","volume":"9","author":"Karakas","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbc.2025.108240_bib8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V91.3.991","article-title":"Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse","volume":"91","author":"Kaufmann","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2025.108240_bib9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.jbc.2025.108240_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-019-0774-x","article-title":"Recent drug approvals for acute myeloid leukemia","volume":"12","author":"Lai","year":"2019","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.jbc.2025.108240_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2025.108240_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jbc.2025.108240_bib13","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jbc.2025.108240_bib14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jbc.2025.108240_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","article-title":"Genetic characterization of ABT-199 sensitivity in human AML","volume":"34","author":"Bisaillon","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jbc.2025.108240_bib16","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","article-title":"Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL","volume":"1","author":"Jayappa","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.jbc.2025.108240_bib17","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","article-title":"Synthetic lethality of combined bcl-2 inhibition and p53 activation in AML: Mechanisms and superior antileukemic efficacy","volume":"32","author":"Pan","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2025.108240_bib18","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jbc.2025.108240_bib19","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2015-12-687814","article-title":"High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells","volume":"128","author":"Oppermann","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2025.108240_bib20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jbc.2025.108240_bib21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2025.108240_bib22","doi-asserted-by":"crossref","first-page":"41425","DOI":"10.1074\/jbc.M111.270843","article-title":"Nucleophosmin interacts with FOXM1 and modulates the level and localization of FOXM1 in human cancer cells","volume":"286","author":"Bhat","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2025.108240_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/leu.2016.270","article-title":"Nuclear FOXM1 drives chemoresistance in AML","volume":"31","author":"Khan","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jbc.2025.108240_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121583","article-title":"FOXM1 contributes to treatment failure in acute myeloid leukemia","volume":"3","author":"Khan","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jbc.2025.108240_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41408-023-00898-4","article-title":"Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance","volume":"13","author":"Khan","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jbc.2025.108240_bib26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41420-024-01929-0","article-title":"Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies","volume":"10","author":"Raghuwanshi","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.jbc.2025.108240_bib27","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbc.2025.108240_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.696532","article-title":"FOXM1-AKT positive regulation loop provides venetoclax resistance in AML","volume":"11","author":"Chesnokov","year":"2021","journal-title":"Front. Oncol."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825000870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825000870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T16:28:23Z","timestamp":1743956903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925825000870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0021925825000870"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2025.108240","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel FOXM1\u2013BCL2A1 axis determines unfavorable response to venetoclax in AML","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2025.108240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology\u00e9","name":"copyright","label":"Copyright"}],"article-number":"108240"}}